RU2331434C2 - Лекарственный препарат, получаемый из плодов королевской пальмы (roystonea regia), и способ его применения для лечения и профилактики простатической гиперплазии и простатита - Google Patents
Лекарственный препарат, получаемый из плодов королевской пальмы (roystonea regia), и способ его применения для лечения и профилактики простатической гиперплазии и простатита Download PDFInfo
- Publication number
- RU2331434C2 RU2331434C2 RU2005130746/15A RU2005130746A RU2331434C2 RU 2331434 C2 RU2331434 C2 RU 2331434C2 RU 2005130746/15 A RU2005130746/15 A RU 2005130746/15A RU 2005130746 A RU2005130746 A RU 2005130746A RU 2331434 C2 RU2331434 C2 RU 2331434C2
- Authority
- RU
- Russia
- Prior art keywords
- acid
- fruits
- roystonea regia
- extract
- fatty acids
- Prior art date
Links
- 235000006595 Roystonea elata Nutrition 0.000 title claims abstract description 89
- 235000013399 edible fruits Nutrition 0.000 title claims abstract description 51
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 title claims abstract description 22
- 208000004403 Prostatic Hyperplasia Diseases 0.000 title claims abstract description 22
- 238000000034 method Methods 0.000 title claims abstract description 17
- 201000007094 prostatitis Diseases 0.000 title claims abstract description 7
- 230000002265 prevention Effects 0.000 title claims abstract description 5
- 240000007186 Roystonea regia Species 0.000 title claims abstract 5
- 238000002360 preparation method Methods 0.000 title abstract description 8
- 241001047505 Archontophoenix alexandrae Species 0.000 title abstract 3
- 201000004240 prostatic hypertrophy Diseases 0.000 title 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims abstract description 18
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 17
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000000194 fatty acid Substances 0.000 claims abstract description 17
- 229930195729 fatty acid Natural products 0.000 claims abstract description 17
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 17
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims abstract description 17
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 claims abstract description 16
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims abstract description 15
- 201000004384 Alopecia Diseases 0.000 claims abstract description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 11
- 238000000605 extraction Methods 0.000 claims abstract description 11
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 claims abstract description 10
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 10
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims abstract description 10
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims abstract description 9
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims abstract description 9
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000005642 Oleic acid Substances 0.000 claims abstract description 9
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims abstract description 9
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims abstract description 9
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims abstract description 9
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims abstract description 8
- 239000005639 Lauric acid Substances 0.000 claims abstract description 8
- 235000021360 Myristic acid Nutrition 0.000 claims abstract description 8
- 235000021314 Palmitic acid Nutrition 0.000 claims abstract description 8
- 235000021319 Palmitoleic acid Nutrition 0.000 claims abstract description 8
- 235000021355 Stearic acid Nutrition 0.000 claims abstract description 8
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 claims abstract description 8
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims abstract description 8
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229960002446 octanoic acid Drugs 0.000 claims abstract description 8
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 claims abstract description 7
- 239000002253 acid Substances 0.000 claims abstract description 7
- 150000007513 acids Chemical class 0.000 claims abstract description 6
- 231100000360 alopecia Toxicity 0.000 claims abstract description 6
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims abstract description 4
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims abstract description 4
- 238000001035 drying Methods 0.000 claims abstract description 4
- 229930195733 hydrocarbon Natural products 0.000 claims abstract description 4
- 150000002430 hydrocarbons Chemical class 0.000 claims abstract description 4
- 239000003960 organic solvent Substances 0.000 claims abstract description 4
- 239000000908 ammonium hydroxide Substances 0.000 claims abstract description 3
- 235000020778 linoleic acid Nutrition 0.000 claims abstract description 3
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims abstract description 3
- 239000004215 Carbon black (E152) Substances 0.000 claims abstract 3
- 238000000227 grinding Methods 0.000 claims abstract 3
- 238000001704 evaporation Methods 0.000 claims abstract 2
- 238000001914 filtration Methods 0.000 claims abstract 2
- 241000899648 Roystonea Species 0.000 claims description 44
- 235000008947 Roystonea oleracea Nutrition 0.000 claims description 41
- 239000000203 mixture Substances 0.000 claims description 23
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 6
- 238000005904 alkaline hydrolysis reaction Methods 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 5
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims description 4
- 229940126601 medicinal product Drugs 0.000 claims description 3
- 239000003513 alkali Substances 0.000 claims description 2
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims 2
- 229910001854 alkali hydroxide Inorganic materials 0.000 claims 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 235000004626 essential fatty acids Nutrition 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000006210 lotion Substances 0.000 claims 1
- 239000002453 shampoo Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000000829 suppository Substances 0.000 claims 1
- -1 tinctures Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 14
- 238000010438 heat treatment Methods 0.000 abstract description 5
- 238000003756 stirring Methods 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 4
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 abstract description 3
- 235000020661 alpha-linolenic acid Nutrition 0.000 abstract description 2
- 230000007062 hydrolysis Effects 0.000 abstract description 2
- 238000006460 hydrolysis reaction Methods 0.000 abstract description 2
- 229960004488 linolenic acid Drugs 0.000 abstract description 2
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 abstract description 2
- 230000008030 elimination Effects 0.000 abstract 1
- 238000003379 elimination reaction Methods 0.000 abstract 1
- 150000002170 ethers Chemical class 0.000 abstract 1
- 230000008020 evaporation Effects 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 abstract 1
- 239000000284 extract Substances 0.000 description 60
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 48
- 244000208347 Roystonea elata Species 0.000 description 44
- 229960003604 testosterone Drugs 0.000 description 24
- 210000002307 prostate Anatomy 0.000 description 22
- 241001465754 Metazoa Species 0.000 description 14
- 230000005764 inhibitory process Effects 0.000 description 14
- 150000002632 lipids Chemical class 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 239000013642 negative control Substances 0.000 description 11
- 241000283973 Oryctolagus cuniculus Species 0.000 description 10
- 239000010018 saw palmetto extract Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 9
- 230000037396 body weight Effects 0.000 description 9
- 241001133760 Acoelorraphe Species 0.000 description 8
- 239000013641 positive control Substances 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 240000006661 Serenoa repens Species 0.000 description 7
- 235000005318 Serenoa repens Nutrition 0.000 description 7
- 229960003473 androstanolone Drugs 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 6
- 230000006978 adaptation Effects 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 235000015112 vegetable and seed oil Nutrition 0.000 description 6
- 239000008158 vegetable oil Substances 0.000 description 6
- 239000003098 androgen Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 230000003676 hair loss Effects 0.000 description 5
- 229940063845 saw palmetto extract Drugs 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 241000233910 Serenoa Species 0.000 description 4
- 235000009108 Urtica dioica Nutrition 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 235000021022 fresh fruits Nutrition 0.000 description 4
- 238000004817 gas chromatography Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 206010046555 Urinary retention Diseases 0.000 description 3
- 244000274883 Urtica dioica Species 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 210000004907 gland Anatomy 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 206010020112 Hirsutism Diseases 0.000 description 2
- DRHKJLXJIQTDTD-OAHLLOKOSA-N Tamsulosine Chemical compound CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 DRHKJLXJIQTDTD-OAHLLOKOSA-N 0.000 description 2
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229960004607 alfuzosin Drugs 0.000 description 2
- WNMJYKCGWZFFKR-UHFFFAOYSA-N alfuzosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CCCNC(=O)C1CCCO1 WNMJYKCGWZFFKR-UHFFFAOYSA-N 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 239000002160 alpha blocker Substances 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 description 2
- 229960001389 doxazosin Drugs 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 2
- 229960004039 finasteride Drugs 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 230000003779 hair growth Effects 0.000 description 2
- 150000004679 hydroxides Chemical class 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 206010029446 nocturia Diseases 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 210000005267 prostate cell Anatomy 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 229940018044 saw palmetto fruit extract Drugs 0.000 description 2
- 238000013222 sprague-dawley male rat Methods 0.000 description 2
- 229960002613 tamsulosin Drugs 0.000 description 2
- 229960001693 terazosin Drugs 0.000 description 2
- VCKUSRYTPJJLNI-UHFFFAOYSA-N terazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 description 2
- 229960001712 testosterone propionate Drugs 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- 244000080767 Areca catechu Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241001456088 Hesperocnide Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 102000004305 alpha Adrenergic Receptors Human genes 0.000 description 1
- 108090000861 alpha Adrenergic Receptors Proteins 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 102000001307 androgen receptors Human genes 0.000 description 1
- 108010080146 androgen receptors Proteins 0.000 description 1
- 201000002996 androgenic alopecia Diseases 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 235000011116 calcium hydroxide Nutrition 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 229940068517 fruit extracts Drugs 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000012977 invasive surgical procedure Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 230000006959 non-competitive inhibition Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 235000011118 potassium hydroxide Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU2003-0062 | 2003-03-20 | ||
| CU20030062A CU23256A1 (es) | 2003-03-20 | 2003-03-20 | EXTRACTO OBTENIDO A PARTIR DE FRUTOS DE ROYSTONEA REGIA UTILIZADO CONTRA LA HIPERPLASIA PROSTáTICA Y LA PROSTATITIS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2005130746A RU2005130746A (ru) | 2006-06-10 |
| RU2331434C2 true RU2331434C2 (ru) | 2008-08-20 |
Family
ID=40210497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005130746/15A RU2331434C2 (ru) | 2003-03-20 | 2004-03-15 | Лекарственный препарат, получаемый из плодов королевской пальмы (roystonea regia), и способ его применения для лечения и профилактики простатической гиперплазии и простатита |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US20060228429A1 (enExample) |
| EP (1) | EP1623740B1 (enExample) |
| JP (1) | JP4693766B2 (enExample) |
| KR (1) | KR100758256B1 (enExample) |
| CN (1) | CN100366246C (enExample) |
| AT (1) | ATE394139T1 (enExample) |
| AU (1) | AU2004222693B2 (enExample) |
| BR (1) | BRPI0409056A (enExample) |
| CA (1) | CA2519410C (enExample) |
| CR (1) | CR8001A (enExample) |
| CU (1) | CU23256A1 (enExample) |
| DE (1) | DE602004013572D1 (enExample) |
| DK (1) | DK1623740T3 (enExample) |
| EC (1) | ECSP056028A (enExample) |
| ES (1) | ES2306999T3 (enExample) |
| IL (1) | IL170997A (enExample) |
| MX (1) | MXPA05009905A (enExample) |
| NO (1) | NO333290B1 (enExample) |
| NZ (1) | NZ542361A (enExample) |
| PT (1) | PT1623740E (enExample) |
| RU (1) | RU2331434C2 (enExample) |
| UA (1) | UA82224C2 (enExample) |
| WO (1) | WO2004082696A1 (enExample) |
| ZA (1) | ZA200507575B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4926395B2 (ja) * | 2004-11-30 | 2012-05-09 | 学校法人 名城大学 | 抗ｍｒｓａ用組成物 |
| KR100769412B1 (ko) * | 2006-09-13 | 2007-10-22 | 주식회사 벤스랩 | Ｐｒ-119 복합생약 추출물을 함유하는 전립선 비대증의예방 및 치료용조성물 |
| WO2010118362A1 (en) | 2009-04-09 | 2010-10-14 | The Regents Of The University Of Colorado, A Body Corporate | Methods and compositions for inducing physiological hypertrophy |
| CU24143B1 (es) * | 2012-06-19 | 2016-01-29 | Cnic Ct Nac Investigaciones | Ingrediente activo para el tratamiento y la prevención de la inflamación y el estrés oxidativo, así como su procedimiento de obtención a partir de los frutos de acrocomina crispa y/o acrocomia aculeata |
| CA2957363C (en) * | 2014-08-12 | 2022-06-21 | Institut de Recherche en Semiochimie et Ethologie Appliquee | Palmitoleic acid for use in inhibiting the attachment of sea lice to fish |
| KR102273967B1 (ko) * | 2014-10-31 | 2021-07-08 | (주)아모레퍼시픽 | 인삼씨유를 함유하여 전립선 비대증을 예방 및 치료하는 조성물 |
| JP2017214342A (ja) * | 2016-06-02 | 2017-12-07 | 日清オイリオグループ株式会社 | 排尿障害の予防用又は改善用組成物 |
| JP6628946B2 (ja) | 2017-12-26 | 2020-01-15 | 大太朗 福岡 | 増毛、頭皮若しくは皮膚の改質、創傷治癒、骨形成促進、または毛髪の改質に用いるための医薬組成物 |
| AU2019212513B2 (en) | 2018-01-26 | 2024-10-31 | Fluidx Medical Technology, Llc | Apparatus and method of using in situ solidifying complex coacervates for vascular occlusion |
| EP4082518A1 (en) | 2021-04-28 | 2022-11-02 | Cnce Innovacion, S.L. | Fatty acid compositions for the treatment and prevention of hair loss and alopecia |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU21519A1 (en) * | 1983-03-23 | 1987-06-09 | Inst De Quimica Y Biolog Ex | Procedure to facilitate the grinding of roystonea regia fruits |
| RU2140265C1 (ru) * | 1998-10-27 | 1999-10-27 | Чернобаев Николай Евгеньевич | Средство для лечения и профилактики доброкачественной гиперплазии простаты (дгп), простатита, импотенции, бесплодия и рака предстательной железы |
| RU2144037C1 (ru) * | 1993-09-17 | 2000-01-10 | Глаксо Веллкам Инк. | Производные андростен(ан)она или его фармацевтически приемлемый сольват, способы их получения, фармацевтический препарат, способ лечения |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1184670A (zh) * | 1997-12-23 | 1998-06-17 | 张冰 | 一种治疗前列腺增生、前列腺炎的药物组合物 |
-
2003
- 2003-03-20 CU CU20030062A patent/CU23256A1/es unknown
-
2004
- 2004-03-15 PT PT04720576T patent/PT1623740E/pt unknown
- 2004-03-15 CN CNB2004800071887A patent/CN100366246C/zh not_active Expired - Lifetime
- 2004-03-15 RU RU2005130746/15A patent/RU2331434C2/ru not_active Application Discontinuation
- 2004-03-15 AU AU2004222693A patent/AU2004222693B2/en not_active Expired
- 2004-03-15 KR KR1020057017600A patent/KR100758256B1/ko not_active Expired - Lifetime
- 2004-03-15 JP JP2006504216A patent/JP4693766B2/ja not_active Expired - Fee Related
- 2004-03-15 UA UAA200508900A patent/UA82224C2/uk unknown
- 2004-03-15 MX MXPA05009905A patent/MXPA05009905A/es active IP Right Grant
- 2004-03-15 DK DK04720576T patent/DK1623740T3/da active
- 2004-03-15 NZ NZ542361A patent/NZ542361A/xx not_active IP Right Cessation
- 2004-03-15 BR BRPI0409056-0A patent/BRPI0409056A/pt not_active IP Right Cessation
- 2004-03-15 CA CA2519410A patent/CA2519410C/en not_active Expired - Fee Related
- 2004-03-15 ES ES04720576T patent/ES2306999T3/es not_active Expired - Lifetime
- 2004-03-15 EP EP04720576A patent/EP1623740B1/en not_active Expired - Lifetime
- 2004-03-15 AT AT04720576T patent/ATE394139T1/de active
- 2004-03-15 US US10/549,740 patent/US20060228429A1/en not_active Abandoned
- 2004-03-15 DE DE602004013572T patent/DE602004013572D1/de not_active Expired - Lifetime
- 2004-03-15 WO PCT/CU2004/000004 patent/WO2004082696A1/es not_active Ceased
-
2005
- 2005-09-19 ZA ZA200507575A patent/ZA200507575B/xx unknown
- 2005-09-20 EC EC2005006028A patent/ECSP056028A/es unknown
- 2005-09-20 IL IL170997A patent/IL170997A/en not_active IP Right Cessation
- 2005-09-20 CR CR8001A patent/CR8001A/es unknown
- 2005-10-20 NO NO20054847A patent/NO333290B1/no not_active IP Right Cessation
-
2009
- 2009-10-08 US US12/575,584 patent/US20100022649A1/en not_active Abandoned
- 2009-10-08 US US12/575,575 patent/US20100021574A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU21519A1 (en) * | 1983-03-23 | 1987-06-09 | Inst De Quimica Y Biolog Ex | Procedure to facilitate the grinding of roystonea regia fruits |
| RU2144037C1 (ru) * | 1993-09-17 | 2000-01-10 | Глаксо Веллкам Инк. | Производные андростен(ан)она или его фармацевтически приемлемый сольват, способы их получения, фармацевтический препарат, способ лечения |
| RU2140265C1 (ru) * | 1998-10-27 | 1999-10-27 | Чернобаев Николай Евгеньевич | Средство для лечения и профилактики доброкачественной гиперплазии простаты (дгп), простатита, импотенции, бесплодия и рака предстательной железы |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20100022649A1 (en) | Pharmaceutical Composition and Procedure to Treat and Prevent Prostatic Hyperplasia and Prostatitis From the Royal Palm (Roystonea regia) Fruits | |
| JPH01168261A (ja) | 燕麦およびイラクサ抽出物の組成物 | |
| RU2203079C2 (ru) | Композиция из трав и способ получения этой композиции для лечения гинекологических заболеваний | |
| EP3113784A1 (en) | Compositions based on plant extracts for inhibition of the 5-alpha reductase | |
| CN111265503B (zh) | 一种抑制5α-还原酶活性的组合物及其应用 | |
| RU2470657C2 (ru) | ПРИМЕНЕНИЕ ЭКСТРАКТОВ ИЛИ ЭКСТРАКТИВНЫХ ВЕЩЕСТВ ИЗ Piper cubeba L. В КАЧЕСТВЕ АКТИВНЫХ ИНГРЕДИЕНТОВ В ЛЕКАРСТВЕННОМ СРЕДСТВЕ ДЛЯ ЛЕЧЕНИЯ РАКОВЫХ ЗАБОЛЕВАНИЙ | |
| JPH05194250A (ja) | サバルセルラタのリピド抽出物の酸分画から導かれた新規薬学的組成物及びその組成物を製造する方法 | |
| Ogunlakin et al. | Ameliorative effect of Kigelia africana (Lam.) Benth. fruit methanol extract in letrozole-induced polycystic ovarian syndrome rat | |
| Nwauche et al. | Assessment of fatty acid, proximate and quantitative phytochemical compositions of matured stem of Costus afer (Bush Cane) | |
| Uroko et al. | Combined ethanol extract of Hypselodelphys poggeana and Spermacoce radiata leaves ameliorate benign prostatic hyperplasia in rats via modulation of serum sex hormonal levels | |
| HK1084059B (en) | Pharmaceutical composition and method for the treatment and prevention of prostatic hyperplasia and prostatitis using roystonea regia (royal palm) fruits | |
| RU2764850C1 (ru) | Способ и средство лечения и профилактики доброкачественной гиперплазии предстательной железы | |
| RU2210380C1 (ru) | Противовоспалительное средство | |
| Sarwar et al. | Piper longum hexane fraction induces infertility by modulation of inflammatory mediators and gonadotripin insufficiency in female rats | |
| AU2012223307A1 (en) | Methods of processing extracts of a T. wilfordii Hook F. plant | |
| CN108938710A (zh) | 烟豆或其提取物在制备治疗和/或预防关节炎的药物中的用途 | |
| Adienbo et al. | Tetrapleura tetraptera (Schum and Thonn) taub fruit extract impairs reproductive hormones and fertility parameters in female experimental rats | |
| Awil et al. | Journal of Cancer Therapy and Research | |
| KR20190126091A (ko) | 전립선 병리상태에서 코파이페라 올레오레진의 용도 | |
| DE102005020330B3 (de) | Verwendung von Extrakten aus Teufelskrallewurzeln (Harpagophytum procumbens) zur Endometriosetherapie | |
| KR20250037836A (ko) | 양성 전립선 비대증(bpt)의 예방 및 개선제 조성물 | |
| JP2020200325A (ja) | 牛蒡抽出物の使用 | |
| HK40017918A (en) | Use of copaifera oleoresin in pathologies of the prostate | |
| Awil et al. | A Natural Product Molecule of Artocarpus Heterophyllus Reverses Inflammation Due to the Effect of Acute Exposure of Prostate Tissue to Testosterone Enanthate in Wistar Rats | |
| KR20030005484A (ko) | 부인과 질환의 치료를 위한 초본 조성물 및 이의 제조방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20071011 |
|
| FZ9A | Application not withdrawn (correction of the notice of withdrawal) |
Effective date: 20071101 |
|
| PC41 | Official registration of the transfer of exclusive right |
Effective date: 20180925 |